B00.1
Conditions
Interventions
Group 1: Compeed Patches (duration of treatment max. 10 days)
Group 2: Herpatch Serum (duration of treatment max. 10 days)
Group 3: Zovirax Creme (duration of treatment max. 10 days)
Sponsors
Sylphar NV
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Male and female patients in the age of 18 till 65 years Written approval of the participant person after clarification Healthy probands, Probands with a finished therapy, without a hurtful tooth or mucosa illness Acute Herpes Simplex labialis
Exclusion criteria
Exclusion criteria: Signs that the patient is unable to comply with the test plan (eg lack of cooperation) Probands with severe general medical disorders The taking of antibiotic or antiphlogistic drugs in the last two weeks prior to study entry The taking of anti-inflammatory drugs during the study period oral diseases, for example Ulcerative gingivitis (NUG), periodontitis colitis (NUP) Immune systeme disorders Known hypersensitivity to the substances used in the study Pregnangcy or lactation Alcohol or drug abuse in the recent past or last year An employee of the sponsor or the study, or a member of their close Family Participation in another clinical study or taking a to examined drug within the 30 days oft he test phase
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary aim is the clinical healing time of Herpatch Serum in contrast to Acyclovir Creme and Compeed Patches. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary aim is the subjective view through the patients and the controller of the study during the 10 days of application (1., 2., 4., 6., 8. and 10. day of treatment) of the products "Herpatch Serum, Acyclovir Creme and Compeed Patches" ("SGAT" subjects global assessment of therapy) using a scale from 0-10, with 0 = no as an answer and 10 = perfect as an answer. | — |
Countries
Germany
Contacts
Public ContactVlasios Goulioumis
Universität Witten/ Herdecke
Outcome results
None listed